{"id":"mk-0954a","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by binding to and blocking NK1 receptors, which are involved in pain transmission and emetic (nausea/vomiting) pathways. By antagonizing these receptors, MK-0954A reduces pain signaling and chemotherapy-induced nausea and vomiting (CINV). This mechanism has been explored for both pain management and antiemetic applications.","oneSentence":"MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:42.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT00307060","phase":"PHASE3","title":"MK0954A-264 Filter Study (0954A-264)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":"Mild to Severe Hypertension","enrollment":274},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT00400218","phase":"PHASE3","title":"Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension","enrollment":62},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":"Essential Hypertension","enrollment":174},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01431508","phase":"PHASE4","title":"A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":"Hypertension","enrollment":15},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00546052","phase":"PHASE3","title":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension, Metabolic Disorder","enrollment":1738},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840},{"nctId":"NCT01368185","phase":"","title":"Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypertension","enrollment":1705}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"NEPHROLITHIASIS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-0954A","genericName":"MK-0954A","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}